Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Comparison of quarterly changes in clinical parameters and CKD-MBD medication use among completers cohortParametersBaselineFollow-upP-value: 1Q; ref (n = 402)Q1 (n = 402)Q2 (n = 402)Q3 (n = 401)Q4 (n = 401)CKD-MBD biochemical markers sP, mg/dL6.26 ± 1.395.80 ± 1.365.64 ± 1.375.73 ± 1.385.79 ± 1.41< 0.0001 sP ≤ 5.5 mg/dL, %32.146.554.051.449.4< 0.0001 sP ≤ 4.5 mg/dL, %6.513.419.917.715.7< 0.0001 Calcium, mg/dL8.99 ± 0.688.92 ± 0.658.91 ± 0.638.87 ± 0.678.86 ± 0.68< 0.0001 Corrected calcium, mg/dL9.52 ± 0.689.46 ± 0.649.44 ± 0.639.41 ± 0.669.39 ± 0.68< 0.0001 iPTH, pg/mL448 ± 359477 ± 372480 ± 369480 ± 338478 ± 3530.14CKD-MBD medications PB pills/daya7.7 ± 3.94.6 ± 1.65.1 ± 2.05.3 ± 2.15.4 ± 2.1< 0.0001 Cinacalcet use, %18.222.926.428.930.6< 0.0001 Oral active vitamin D use, %58.061.765.765.462.20.0002Nutritional and clearance parameters Serum albumin, g/dL3.67 ± 0.403.63 ± 0.393.62 ± 0.383.59 ± 0.403.59 ± 0.40< 0.0001 Phosphorus-attuned albumin, × 10³0.62 ± 0.160.67 ± 0.170.69 ± 0.1720.67 ± 0.170.67 ± 0.17< 0.0001 nPCR, g/kg/day1.07 ± 0.281.07 ± 0.281.05 ± 0.291.05 ± 0.321.04 ± 0.280.13 PD Kt/V, dialysis + Kru2.26 ± 0.902.26 ± 0.622.21 ± 0.592.19 ± 0.622.19 ± 0.550.17 Dialysis Kt/V1.39 ± 0.421.42 ± 0.501.42 ± 0.381.47 ± 0.571.48 ± 0.49< 0.0001 Kru, mL/min3.99 ± 5.533.79 ± 2.573.75 ± 2.793.41 ± 2.823.37 ± 2.74< 0.0001Values are presented as arithmetic mean ± SD for continuous variables.
Source: Changes in serum phosphorus and pill burden by residual kidney function. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Adult FKC patients aged 18 years and older who dialyzed with PD and received SO monotherapy between May 2018 and December 2019 as part of their routine care were included in the analysis.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis
Study design awaiting verification · BMC Nephrology · 2024
Original publication title
Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Hyperphosphatemia is associated with increased morbidity and mortality in patients with end-stage kidney disease (ESKD). Whereas clinical and observational studies have demonstrated the effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus (sP) in ESKD, data on the real-world impact of switching to SO in patients on peritoneal dialysis (PD) are limited. In this retrospective database analysis, we examine the impact of SO on sP management over a 1-year period among PD patients prescribed SO as part of routine clinical care.
Source: BackgroundAbstract: What methods does the paper describe?
We analyzed de-identified data from adults on PD in Fresenius Kidney Care clinics who were prescribed SO monotherapy between May 2018 and December 2019 as part of routine clinical management. Changes from baseline in sP levels, phosphate binder (PB) pill burden, and laboratory parameters were evaluated during the four consecutive 91-day intervals of SO treatment.
Source: MethodsAbstract: Results
The mean age of the 402 patients who completed 1 year of SO was 55.2 years at baseline, and they had been on PD for an average of 19.9 months. SO was initiated with no baseline PB recorded in 36.1% of patients, whereas the remaining 257 patients were switched to SO from sevelamer (39.7%), calcium acetate (30.4%), lanthanum (1.2%), ferric citrate (14.0%), or more than one PB (14.8%). Mean sP at baseline was 6.26 mg/dL. After being prescribed SO, the percentage of patients achieving sP ≤ 5.5 mg/dL increased from 32.1% (baseline) to 46.5 to 54.0% during the 1-year follow-up, whereas the mean number of PB pills taken per day decreased from 7.7 at baseline (among patients on a baseline PB) to 4.6 to 5.4.
Serum phosphorus and PB pill burden decreased regardless of changes in residual kidney function over the 12-month period. Similar results were observed for the full cohort (976 patients who either completed or discontinued SO during the 1-year follow-up).
Source: ResultsAbstract: Conclusions
Patients on PD who were prescribed SO as part of routine care for phosphorus management experienced significant reductions in SP and PB pills per day and improvements in sP target achievement, suggesting the effectiveness of SO on SP management with a concurrent reduction in pill burden.
Source: ConclusionsAuthors’ abstract
Background
Hyperphosphatemia is associated with increased morbidity and mortality in patients with end-stage kidney disease (ESKD). Whereas clinical and observational studies have demonstrated the effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus (sP) in ESKD, data on the real-world impact of switching to SO in patients on peritoneal dialysis (PD) are limited. In this retrospective database analysis, we examine the impact of SO on sP management over a 1-year period among PD patients prescribed SO as part of routine clinical care.
Methods
We analyzed de-identified data from adults on PD in Fresenius Kidney Care clinics who were prescribed SO monotherapy between May 2018 and December 2019 as part of routine clinical management. Changes from baseline in sP levels, phosphate binder (PB) pill burden, and laboratory parameters were evaluated during the four consecutive 91-day intervals of SO treatment.
Results
The mean age of the 402 patients who completed 1 year of SO was 55.2 years at baseline, and they had been on PD for an average of 19.9 months. SO was initiated with no baseline PB recorded in 36.1% of patients, whereas the remaining 257 patients were switched to SO from sevelamer (39.7%), calcium acetate (30.4%), lanthanum (1.2%), ferric citrate (14.0%), or more than one PB (14.8%). Mean sP at baseline was 6.26 mg/dL. After being prescribed SO, the percentage of patients achieving sP ≤ 5.5 mg/dL increased from 32.1% (baseline) to 46.5 to 54.0% during the 1-year follow-up, whereas the mean number of PB pills taken per day decreased from 7.7 at baseline (among patients on a baseline PB) to 4.6 to 5.4.
Serum phosphorus and PB pill burden decreased regardless of changes in residual kidney function over the 12-month period. Similar results were observed for the full cohort (976 patients who either completed or discontinued SO during the 1-year follow-up).
Conclusions
Patients on PD who were prescribed SO as part of routine care for phosphorus management experienced significant reductions in SP and PB pills per day and improvements in sP target achievement, suggesting the effectiveness of SO on SP management with a concurrent reduction in pill burden.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12882-024-03633-8.
Publication and source details
Original title: Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis
Kamyar Kalantar-Zadeh; Linda H. Ficociello; Meijiao Zhou; Michael S. Anger
BMC Nephrology · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Fresenius Medical CareRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T10:57:27.335952+00:00
DOI: 10.1186/s12882-024-03633-8 · PMC11184799